Loic Ysebaert

List of Publications by Year
in descending order

193 papers	6,259 citations	87723 38 h-index	79541 73 g-index
199 all docs	199 docs citations	199 times ranked	8147 citing authors

#	Article	IF	Citations
1	Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood, 2011, 117, 1834-1839.	0.6	346
2	Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood, 2014, 124, 3991-3995.	0.6	265
3	Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. New England Journal of Medicine, 2018, 379, 934-947.	13.9	264
4	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 525-533.	5.1	257
5	The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study. Journal of Clinical Oncology, 2011, 29, 4079-4087.	0.8	248
6	Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood, 2018, 131, 1955-1959.	0.6	232
7	Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Advances, 2020, 4, 5607-5615.	2.5	222
8	Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood, 2017, 129, 2471-2478.	0.6	200
9	Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematology,the, 2017, 4, e114-e126.	2.2	181
10	Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. Journal of Clinical Oncology, 2019, 37, 2815-2824.	0.8	173
11	What lessons can be learned from Î³Î´ T cell-based cancer immunotherapy trials?. Cellular and Molecular Immunology, 2013, 10, 35-41.	4.8	164
12	Anaplastic Lymphoma Kinaseâ€“Positive Diffuse Large B-Cell Lymphoma: A Rare Clinicopathologic Entity With Poor Prognosis. Journal of Clinical Oncology, 2009, 27, 4211-4216.	0.8	154
13	Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVÎ´1 and TCRVÎ´2 Î³Î´ T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11906-11915.	3.3	152
14	MYC + diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood, 2012, 119, 4619-4624.	0.6	145
15	Expression of Focal Adhesion Kinase in Acute Myeloid Leukemia Is Associated with Enhanced Blast Migration, Increased Cellularity, and Poor Prognosis. Cancer Research, 2004, 64, 3191-3197.	0.4	140
16	Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood, 2009, 113, 4875-4884.	0.6	123
17	Hepatitis E virus excretion can be prolonged in patients with hematological malignancies. Journal of Clinical Virology, 2010, 49, 141-144.	1.6	120
18	Atrial fibrillation in <scp>CLL</scp> patients treated with ibrutinib. An international retrospective study. British Journal of Haematology, 2016, 175, 462-466.	1.2	113

#	Article	IF	Citations
19	Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. Blood, 2015, 126, 2110-2117.	0.6	94
20	Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). Journal of Clinical Oncology, 2022, 40, 242-251.	0.8	90
21	Efficacy of chemotherapy or chemoâ€antiâ€PDâ€1 combination after failed antiâ€PDâ€1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers. American Journal of Hematology, 2018, 93, 1042-1049.	2.0	87
22	Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica, 2011, 96, 1136-1143.	1.7	84
23	Several immune escape patterns in non-Hodgkin's lymphomas. OncoImmunology, 2015, 4, e1026530.	2.1	82
24	Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood, 2019, 134, 641-644.	0.6	77
25	Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T-cell lymphoma. Blood, 2012, 120, 3997-4005.	0.6	68
26	Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation). International Journal of Radiation Oncology Biology Physics, 2004, 58, 1128-1134.	0.4	63
27	Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood, 2019, 133, 2765-2775.	0.6	63
28	Longâ€term followâ€up and second malignancies in 487 patients with hairy cell leukaemia. British Journal of Haematology, 2014, 166, 390-400.	1.2	53
29	A revised international prognostic score system for WaldenstrÃ¶mâ€™s macroglobulinemia. Leukemia, 2019, 33, 2654-2661.	3.3	53
30	Boosting Î³Î´ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma. OncoImmunology, 2019, 8, 1554175.	2.1	53
31	Dermatological Toxicities of Brutonâ€™s Tyrosine Kinase Inhibitors. American Journal of Clinical Dermatology, 2020, 21, 799-812.	3.3	50
32	Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. Blood, 2020, 135, 996-1007.	0.6	49
33	A New Î±5Î²1 Integrin-Dependent Survival Pathway Through GSK3Î² Activation in Leukemic Cells. PLoS ONE, 2010, 5, e9807.	1.1	45
34	Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia. Haematologica, 2013, 98, 65-70.	1.7	44
35	Cell Adhesion Regulates CDC25A Expression and Proliferation in Acute Myeloid Leukemia. Cancer Research, 2006, 66, 7128-7135.	0.4	43
36	Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. Haematologica, 2020, 106, 87-97.	1.7	43

#	Article	IF	Citations
37	Genomic and phenotypic characterization of nurse-like cells that promote drug resistance in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2011, 52, 1404-1406.	0.6	42
38	Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies. Emerging Infectious Diseases, 2015, 21, 1466-1469.	2.0	41
39	Effectiveness of telephone support during chemotherapy in patients with diffuse large B cell lymphoma: The Ambulatory Medical Assistance (AMA) experience. International Journal of Nursing Studies, 2011, 48, 926-932.	2.5	39
40	Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions. Haematologica, 2019, 104, 2292-2299.	1.7	39
41	A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma. Haematologica, 2019, 104, 138-146.	1.7	37
42	Nurse like cells: chronic lymphocytic leukemia associated macrophages. Leukemia and Lymphoma, 2015, 56, 1570-1572.	0.6	36
43	Bendamustine is effective in Tâ€Cell prolymphocytic leukaemia. British Journal of Haematology, 2015, 168, 916-919.	1.2	36
44	Bendamustine and rituximab combination in the management of chronic lymphocytic leukemiaâ€associated autoimmune hemolytic anemia: A multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS). American Journal of Hematology, 2015, 90, 204-207.	2.0	33
45	Impaired functional responses in follicular lymphoma CD8⁺TIM-3⁺T lymphocytes following TCR engagement. OncoImmunology, 2016, 5, e1224044.	2.1	32
46	Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients. British Journal of Haematology, 2017, 176, 37-49.	1.2	32
47	Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in firstâ€line chronic lymphocytic leukemia. Hematological Oncology, 2017, 35, 664-670.	0.8	32
48	L-selectin controls trafficking of chronic lymphocytic leukemia cells in lymph node high endothelial venules in vivo. Blood, 2015, 126, 1336-1345.	0.6	30
49	Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC. Blood, 2015, 126, 3979-3979.	0.6	30
50	Recombinant Human IL-15 Trans-Presentation by B Leukemic Cells from Chronic Lymphocytic Leukemia Induces Autologous NK Cell Proliferation Leading to Improved Anti-CD20 Immunotherapy. Journal of Immunology, 2013, 191, 3634-3640.	0.4	28
51	Nurse-like cells promote CLL survival through LFA-3/CD2 interactions. Oncotarget, 2017, 8, 52225-52236.	0.8	28
52	Realâ€world results of ibrutinib in relapsed/refractory <scp>CLL</scp> in <scp>F</scp>rance: Early results on a large series of 428 patients. American Journal of Hematology, 2017, 92, E166-E168.	2.0	27
53	Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study. PLoS ONE, 2016, 11, e0162965.	1.1	27
54	Rituximabâ€“cyclophosphamideâ€“dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2011, 52, 1401-1403.	0.6	26

#	Article	IF	Citations
55	Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO). HemaSphere, 2020, 4, e473.	1.2	26
56	Epidermal Growth Factor Receptor/Î²-Catenin/T-Cell Factor 4/Matrix Metalloproteinase 1: A New Pathway for Regulating Keratinocyte Invasiveness after UVA Irradiation. Cancer Research, 2009, 69, 3291-3299.	0.4	25
57	Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia. Leukemia Research, 2013, 37, 440-446.	0.4	24
58	PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 215-221.	3.3	24
59	Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The <scp>F</scp>rench intergroup experience. American Journal of Hematology, 2015, 90, 511-514.	2.0	23
60	Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort. Annals of Hematology, 2021, 100, 987-993.	0.8	23
61	Immune thrombocytopenic purpura following human papillomavirus vaccination. Vaccine, 2009, 27, 3690.	1.7	22
62	Hemoglobin concentration; a pathway to frailty. BMC Geriatrics, 2020, 20, 202.	1.1	22
63	BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Blood, 2021, 137, 3495-3506.	0.6	22
64	Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. Clinical Pharmacokinetics, 2017, 56, 635-647.	1.6	21
65	Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. Lancet Haematology,the, 2019, 6, e470-e479.	2.2	20
66	Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia. Leukemia, 2019, 33, 2531-2535.	3.3	20
67	Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma. Blood, 2020, 136, 32-33.	0.6	20
68	Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies. Expert Opinion on Investigational Drugs, 2011, 20, 1167-1174.	1.9	19
69	Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse. Biomarker Research, 2020, 8, 72.	2.8	19
70	Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group. Genes Chromosomes and Cancer, 2018, 57, 533-540.	1.5	18
71	CIP4 Controls CCL19-Driven Cell Steering and Chemotaxis in Chronic Lymphocytic Leukemia. Cancer Research, 2013, 73, 3412-3424.	0.4	17
72	New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. Experimental Hematology and Oncology, 2015, 5, 7.	2.0	17

#	Article	IF	Citations
73	Frontline Therapy with the Ribvd Regimen Elicits High Clinical and Molecular Response Rates and Long PFS in Elderly Patients Mantle Cell Lymphoma (MCL); Final Results of a Prospective Phase II Trial By the Lysa Group. Blood, 2014, 124, 148-148.	0.6	17
74	Baseline SUV_{max} is related to tumor cell proliferation and patient outcome in follicular lymphoma. Haematologica, 2022, 107, 221-230.	1.7	17
75	Bendamustine for relapsed blastic plasmacytoid dendritic cell leukaemia. Hematological Oncology, 2017, 35, 252-255.	0.8	16
76	Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study. Blood Advances, 2020, 4, 3217-3223.	2.5	16
77	Targeting Kinases in Cancer Therapies: Adverse Effects on Blood Platelets. Current Pharmaceutical Design, 2016, 22, 2315-2322.	0.9	16
78	Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. Leukemia, 2021, 35, 1597-1609.	3.3	15
79	Longâ€term fatigue in survivors of nonâ€Hodgkin lymphoma: The Lymphoma Study Association SIMONAL crossâ€sectional study. Cancer, 2019, 125, 2291-2299.	2.0	14
80	Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data . OncoTargets and Therapy, 2020, Volume 13, 5199-5205.	1.0	14
81	Lymphoproliferative disease in patients with Wiskott-Aldrich syndrome: Analysis of the French Registry of Primary Immunodeficiencies. Journal of Allergy and Clinical Immunology, 2019, 143, 2311-2315.e7.	1.5	13
82	Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies. Clinical Pharmacokinetics, 2020, 59, 1171-1183.	1.6	13
83	Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. Leukemia, 2021, 35, 2108-2113.	3.3	13
84	Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High-Dose Therapy with Stem Cell Transplantation in Poor-Risk Patients with Diffuse Large B Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, 1905-1911.	2.0	12
85	Small nucleolar RNA expression profiles refine the prognostic impact of IGHV mutational status on treatmentâ€free survival in chronic lymphocytic leukaemia. British Journal of Haematology, 2016, 172, 819-823.	1.2	12
86	Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A realâ€world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group. American Journal of Hematology, 2017, 92, E105-E107.	2.0	12
87	Ibrutinib and idelalisib in the management of CLLâ€associated autoimmune cytopenias: a study from the FILO group. American Journal of Hematology, 2019, 94, E183-E185.	2.0	12
88	Doseâ€limiting stomatitis associated with ibrutinib therapy: a case series. British Journal of Haematology, 2019, 185, 784-788.	1.2	12
89	Insights on TAM Formation from a Boolean Model of Macrophage Polarization Based on In Vitro Studies. Cancers, 2020, 12, 3664.	1.7	12
90	Impact of a comprehensive geriatric assessment on decisionâ€making in older patients with hematological malignancies. European Journal of Haematology, 2021, 106, 616-626.	1.1	12

#	Article	IF	Citations
91	First immunochemotherapy outcomes in elderly patients with CLL: A retrospective analysis. Journal of Geriatric Oncology, 2013, 4, 141-147.	0.5	11
92	Phased differentiation of Î³Î´ T and T CD8 tumor-infiltrating lymphocytes revealed by single-cell transcriptomics of human cancers. OncoImmunology, 2021, 10, 1939518.	2.1	11
93	IL-10 Rescues CLL Survival through Repolarization of Inflammatory Nurse-like Cells. Cancers, 2022, 14, 16.	1.7	11
94	Characterization of Bone Marrow Lymphoid Infiltrates After Immunochemotherapy for Follicular Lymphoma. American Journal of Clinical Pathology, 2007, 128, 974-980.	0.4	10
95	Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies. Current Drug Targets, 2010, 11, 790-800.	1.0	10
96	A fixed-duration, measurable residual diseaseâ€“guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial. Blood, 2021, 137, 1019-1023.	0.6	10
97	CC-122 Expands Activated and Memory CD4 and CD8 T Cells In Vivo and Induces T Cell Activation Ex Vivo in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma and Multiple Myeloma. Blood, 2015, 126, 2704-2704.	0.6	10
98	Disseminated Cryptococcosis. New England Journal of Medicine, 2014, 370, 1741-1741.	13.9	9
99	Rituximabâ€“cyclophosphamideâ€dexamethasone is highly effective in patients with monoclonal <scp>I</scp>g depositâ€related glomerulopathy and indolent nonâ€<scp>H</scp>odgkin lymphomas. American Journal of Hematology, 2014, 89, 969-973.	2.0	9
100	Bruton's tyrosine kinase inhibitors. Current Opinion in Oncology, 2014, 26, 463-468.	1.1	9
101	Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia. BMC Cancer, 2019, 19, 809.	1.1	9
102	Targeted therapy of BRAF V600Eâ€mutant histiocytic sarcoma: A case report and review of the literature. European Journal of Haematology, 2019, 103, 444-448.	1.1	9
103	Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia.. Annals of Hematology, 2019, 98, 931-939.	0.8	9
104	ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 779-783.	1.4	9
105	Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients. Leukemia and Lymphoma, 2021, 62, 846-853.	0.6	9
106	Lymphoma Heterogeneity Unraveled by Single-Cell Transcriptomics. Frontiers in Immunology, 2021, 12, 597651.	2.2	9
107	A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the â€œREal world dAta in LYmphoma and survival in adultsâ€•(REALYSA) cohort. BMC Public Health, 2021, 21, 432.	1.2	9
108	3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma. Cancers, 2021, 13, 1490.	1.7	9

#	Article	IF	Citations
109	The Impact of Atrial Fibrillation on Subsequent Survival of Patients Receiving Ibrutinib As Treatment of Chronic Lymphocytic Leukemia (CLL): An International Study. Blood, 2016, 128, 3242-3242.	0.6	9
110	Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies. Oncotarget, 2016, 7, 85937-85947.	0.8	9
111	Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells. Leukemia and Lymphoma, 2012, 53, 966-972.	0.6	8
112	Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivo. Journal of Thrombosis and Haemostasis, 2020, 18, 3336-3351.	1.9	8
113	Prospective, Multicentric Phase II Randomized Trial Comparing the Efficacy of Methotrexate or Cyclophosphamide in Large Granular Lymphocytic Leukemia: A French National Study. Report on the Interim Analysis. Blood, 2019, 134, 1545-1545.	0.6	8
114	Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?. Leukemia and Lymphoma, 2012, 53, 362-370.	0.6	7
115	Venetoclax to treat relapsed blastic plasmacytoid dendritic cell neoplasm: A case-report and review of literature. Leukemia Research, 2019, 85, 106199.	0.4	7
116	France: The First Country to Ban a Type of Breast Implant Linked to Anaplastic Large Cell Lymphoma. Aesthetic Surgery Journal, 2019, 39, NP352-NP353.	0.9	7
117	Overall survival benefit of symptom monitoring in real-world patients with chronic lymphocytic leukaemia treated with ibrutinib: a FiLO group study. European Journal of Cancer, 2020, 135, 170-172.	1.3	7
118	Venetoclax with highâ€dose methotrexate and rituximab seem effective and wellâ€tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report. Clinical Case Reports (discontinued), 2020, 8, 269-273.	0.2	7
119	CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma. Blood, 2015, 126, 1494-1494.	0.6	7
120	Clinical activity of a new regimen combining gemcitabine and alemtuzumab in highâ€risk relapsed/refractory chronic lymphocytic leukemia patients. European Journal of Haematology, 2015, 94, 37-42.	1.1	6
121	Bendamustine plus rituximab for indolent Bâ€cell lymphoma of renal significance. American Journal of Hematology, 2018, 93, 356-362.	2.0	6
122	Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients. Open Forum Infectious Diseases, 2019, 6, ofz345.	0.4	6
123	Multiparametric analysis of CD8⁺ T cell compartment phenotype in chronic lymphocytic leukemia reveals a signature associated with progression toward therapy. OncoImmunology, 2019, 8, e1570774.	2.1	6
124	Relative Impact of NOTCH1/SF3B1 Mutations, Complex Karyotype and TP53 Disruption in the Prognosis of Chronic Lymphocytic Leukemia Patients.. Blood, 2012, 120, 2879-2879.	0.6	6
125	Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma. Journal of Oncology Pharmacy Practice, 2021, 27, 1730-1735.	0.5	5
126	Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data. Pharmaceuticals, 2021, 14, 162.	1.7	5

#	Article	IF	Citations
127	Elucidation of Mild Bleeding Disorders Reported Under Ibrutinib (Imbruvica(R)) Therapy: Implications for Optimal Clinical Management. Blood, 2014, 124, 3296-3296.	0.6	5
128	Efficacy of Chemotherapy or Chemo-Anti-PD-1 Combination after Unsatisfactory Response of Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Retrospective Series from Lysa Centers. Blood, 2017, 130, 652-652.	0.6	5
129	Sustained degradation of quality of life in a subgroup of lymphoma survivors: a two-year prospective survey. BMC Cancer, 2019, 19, 1178.	1.1	4
130	High Prevalence of BTK Mutations on Ibrutinib Therapy after 3 Years of Treatment in a Real-Life Cohort of CLL Patients: A Study from the French Innovative Leukemia Organization (FILO) Group. Blood, 2018, 132, 584-584.	0.6	4
131	The Ribvd Regimen (Rituximab IV, Bendamustine IV, Velcade SC, Dexamethasone IV) Offers a High Complete Response Rate In Elderly Patients With Untreated Mantle Cell Lymphoma. Preliminary Results Of The Lysa Trial â€œLymphome Du Manteau 2010 SAâ€. Blood, 2013, 122, 370-370.	0.6	4
132	Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial. Blood, 2014, 124, 3341-3341.	0.6	4
133	An evaluation of the chronic lymphocytic leukemia (CLL) international prognostic index as a prognostic tool in patients with relapsed/refractory CLL in idelalisib phase 3 randomized studies.. Journal of Clinical Oncology, 2016, 34, 7513-7513.	0.8	4
134	Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology, 2016, 34, 7515-7515.	0.8	4
135	Management of elderly patients with chronic lymphocytic leukemia in the era of targeted therapies. Current Opinion in Oncology, 2015, 27, 365-370.	1.1	3
136	Asymptomatic circulating T-cell clone cause renal polymorphic inflammatory fibrosis. Clinical and Experimental Nephrology, 2017, 21, 781-786.	0.7	3
137	Firstâ€line therapy for chronic lymphocytic leukemia in patients older than 79Âyears is feasible and achieves good results: A FILO retrospective study. Hematological Oncology, 2017, 35, 671-678.	0.8	3
138	Onsets of progression and second treatment determine survival of patients with symptomatic WaldenstrÃ¶m macroglobulinemia. Blood Advances, 2018, 2, 3102-3111.	2.5	3
139	Exclusive Bâ€cell phenotype of primary prostatic lymphomas: a potential role of chronic prostatitis. Histopathology, 2020, 76, 767-773.	1.6	3
140	Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial. Blood, 2019, 134, 1524-1524.	0.6	3
141	Efficacy of dupilumab in eosinophilic dermatosis of haematologic malignancy (EDHM) needs to be confirmed. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	3
142	Does early disease progression predict survival after first lineâ€treatment of WaldenstrÃ¶m macroglobulinemia?. Hematological Oncology, 2022, 40, 400-408.	0.8	3
143	DNA polymerase Î½ gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status. Haematologica, 2018, 103, 1038-1046.	1.7	2
144	Immunomodulatory Agents in Follicular Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 715-726.	0.9	2

#	Article	IF	Citations
145	Population PKâ€PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment. Clinical Pharmacology and Therapeutics, 2021, 110, 220-228.	2.3	2
146	Blinatumomab after R-CHOP Debulking Therapy for Patients with Richter Transformation: Preliminary Results of the Multicenter Phase 2 Blinart Trial from the Filo Group. Blood, 2020, 136, 4-5.	0.6	2
147	Ibrutinib Exposure and B-Cell Depletion Induced By Anti-CD20 Monoclonal Antibodies Rituximab and Obinutuzumab: Is There a Rationale for Combination Studies?. Blood, 2014, 124, 1980-1980.	0.6	2
148	CLL Cells from Ibrutinib-Induced Lymphocytosis of Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Are Responsive to Obinutuzumab, but Not Rituximab, Ex Vivo. Blood, 2015, 126, 4157-4157.	0.6	2
149	Final results of a randomized phase II GELA/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2014, 32, 8503-8503.	0.8	2
150	Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. "the TOTAL Trial". Blood, 2020, 136, 15-16.	0.6	2
151	Spectrum of Kidney Disorders Associated with T-Cell Immunoclones. Journal of Clinical Medicine, 2022, 11, 604.	1.0	2
152	T cells in CLL: lost in migration. Blood, 2013, 121, 2580-2582.	0.6	1
153	Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO). American Journal of Hematology, 2018, 93, E52-E54.	2.0	1
154	On the BALL to spot the best score able to predict overall survival in relapsed or refractory CLL. Lancet Haematology,the, 2019, 6, e343-e344.	2.2	1
155	Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (<scp>FILO</scp>). American Journal of Hematology, 2021, 96, E353-E356.	2.0	1
156	Non-Interventional Retrospective Multicenter Study Evaluating Real Word Idelalisib Use in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma Patients Enrolled in the French Early Access Program. Blood, 2018, 132, 5924-5924.	0.6	1
157	Kinase Inhibitors (ibrutinib or idelalisib) in the Management of Chronic Lymphocytic Leukemia-Associated Autoimmune Cytopenia: A Retrospective Study of the French Innovative Leukemia Organization (FILO). Blood, 2018, 132, 3152-3152.	0.6	1
158	A French Multicentric Prospective Cohort of 6000 Patients with Integrative Epidemiological, Clinical, Biological and Treatment Data to Improve Knowledge on Outcome of Lymphoma Patients: Pilot Phase Results of the Real World Data in Lymphoma and Survival in Adults (REALYSA) Study. Blood, 2019, 134, 4762-4762.	0.6	1
159	Mutational Landscape of 118 Relapsed Chronic Lymphocytic Leukemia Clinical Trial Samples; Evidence for a Multiple-Hit Profile Using Targeted Next Generation Sequencing. Blood, 2014, 124, 1974-1974.	0.6	1
160	Central Nervous System Involvement in Chronic Lymphocytic Leukemia: Diagnosis and Treatment in a Retrospective Cohort of Thirty Patients. Blood, 2015, 126, 2948-2948.	0.6	1
161	First Line Chronic Lymphocytic Leukemia Immunochemotherapy for the Elderly Patients over 79 Years Is Feasible, and Achieves Good Results: A Filo Retrospective Study. Blood, 2015, 126, 4170-4170.	0.6	1
162	Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study.. Journal of Clinical Oncology, 2016, 34, 7518-7518.	0.8	1

#	Article	IF	Citations
163	Economic burden in nonâ€Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL crossâ€sectional study. Cancer, 2021, , .	2.0	1
164	Clinical and Biological Characteristics Associated with In Vitro Activity of Anti-CD20 Monoclonal Antibodies, Rituximab and GA101, Against Chronic Lymphocytic Leukemia Cells. Blood, 2010, 116, 2459-2459.	0.6	1
165	Salvage Therapies in Patients with High-Risk Relapse After Fludarabine, Cyclophosphamide, Rituximab (FCR) for Chronic Lymphocytic Leukemia: The French CLL Intergroup Experience. Blood, 2012, 120, 1796-1796.	0.6	1
166	Management of bleedings and prevention recommendations in patients taking ibrutinib for lymphoma therapy. Hematologie, 2015, 21, 230-233.	0.0	1
167	Outcomes of patients with relapsed and refractory chronic lymphocytic leukemia (CLL) who discontinue idelalisib treatment.. Journal of Clinical Oncology, 2016, 34, 7531-7531.	0.8	1
168	Real-World Ibrutinib Validation of the Ball Score to Predict Overall Survival: A Filo Group Study in RR CLL Patients. Blood, 2019, 134, 1741-1741.	0.6	1
169	Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia (CLL) and Budget Impact Analysis of Venetoclax Plus Obinutuzumab Sequences for CLL Patients Not Eligible for Full Dose Fludarabine in France. Blood, 2020, 136, 28-29.	0.6	1
170	Targetting BTK/PI-3KÎ´ in CLL. Hematologie, 2015, 21, 117-126.	0.0	0
171	19. Translating science into therapy of lymphoma. , 2016, , 379-402.		0
172	High Frequency of Mutations in BTK and PLCG2 in Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S217-S218.	0.2	0
173	Nivolumab in refractory cerebral relapse of Hodgkinâ€™s lymphoma. Leukemia and Lymphoma, 2021, 62, 1-3.	0.6	0
174	Chronic Lymphocytic Leukemia-Associated Macrophages: Not Just Nurse Cells. Blood, 2010, 116, 46-46.	0.6	0
175	Rituximab-Cyclophosphamide-Dexamethasone (RCD) Combination In the Management of Autoimmune Cytopenias Associated with Chronic Lymphocytic Leukaemia. Blood, 2010, 116, 2451-2451.	0.6	0
176	PET Evaluation Before Autografting Has a Strong Prognostic Impact in High-Risk, Relapsed Follicular Lymphoma Patients. Blood, 2011, 118, 1612-1612.	0.6	0
177	Granulocyte-Colony Stimulating Factor Use in Young Fit CLL Patients Receiving Fludarabine-Cyclophosphamide-Rituximab Frontline: Impact on Outcomes, Relative Dose Intensity and Toxicities. Blood, 2011, 118, 1798-1798.	0.6	0
178	Small Nucleolar RNA Expression Profiling Identifies Potential Prognostic Markers in Peripheral T-Cell Lymphoma.. Blood, 2012, 120, 2678-2678.	0.6	0
179	Improved Outcome After Allogeneic Stem-Cell Transplantation (SCT) As Compared to Non-Allogeneic SCT Therapies in Patients with High-Risk Peripheral T-Cell Lymphomas in First Response.. Blood, 2012, 120, 3111-3111.	0.6	0
180	Lymphocyte Function-Associated Antigen 3 (LFA-3): Key Factor of the Interactions Between Nurse-like-Cells and B Leukemic Cells from Chronic Lymphocytic Leukemia. Blood, 2014, 124, 1955-1955.	0.6	0

#	Article	IF	Citations
181	Minimal Residual Disease Monitoring By 8-Color Flow Cytometry in Mantle Cell Lymphoma Is Complementary to Q-PCR Monitoring and Will Facilitate Pre-Emptive Treatment: An EU-MCL and Lysa Study. Blood, 2014, 124, 1657-1657.	0.6	0
182	Abstract 5203: Innovative and predictive models against cancer: an IMODI integrative approach. , 2016, , .		0
183	Efficacy of the Ribvd Regimen in High Risk Mantle Cell Lymphoma Patients As Defined By the Mipic Prognostic Score: Identification of KI67, LDH and Performance Status As Most Important Prognostic Factors (PF). a French Lysa Group Study. Blood, 2016, 128, 5302-5302.	0.6	0
184	High Rate of Complete Response (CR) with Undetectable Bone Marrow Minimal Residual Disease (MRD) after Chemo-Sparing and MRD-Driven Strategy for Untreated Fit CLL Patients: Final Results of the Icll 07 Filo Trial. Blood, 2018, 132, 1858-1858.	0.6	0
185	p53 Functional Assessment and Correlation with 17p Deletion and/or TP53 Mutation Status: Final Report of the ICLL001 Bomp Trial. Blood, 2018, 132, 3127-3127.	0.6	0
186	Real-Word Clinical Management of Patients Treated with Idelalisib in France: A Study of 529 Cases of Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphoma (FL). Blood, 2018, 132, 2302-2302.	0.6	0
187	Boosting Gamma Delta T Cells-Mediated ADCC By PD-1 Blockade in Follicular Lymphoma. Blood, 2018, 132, 5381-5381.	0.6	0
188	Interest of Dosing of Ibrutinib in B-Cell Lymphoid Malignancies: Data from a Real-Life, Phase 4 Study. Blood, 2018, 132, 3960-3960.	0.6	0
189	Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial. Blood, 2019, 134, 3038-3038.	0.6	0
190	Semi-automatic segmentation of whole-body images in longitudinal studies. Biomedical Physics and Engineering Express, 2021, 7, 015014.	0.6	0
191	ELEVATE-RR â€“ first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia. Journal of Modern Oncology, 2021, 23, 404-406.	0.1	0
192	Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement. Blood, 2020, 136, 29-30.	0.6	0
193	â€œAccelerated phaseâ€•chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies. Hematological Oncology, 2022, 40, 805-808.	0.8	0